ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ロフルミラスト

Roflumilast

HCID 449193
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
162401-32-3
標準SMILES
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
InChIKey
MNDBXUUTURYVHR-UHFFFAOYSA-N
分子式
C17H14Cl2F2N2O3
平均分子量
403.2 g/mol
単同位体質量
402.034954

概要

Roflumilast is a benzamide obtained by formal condensation of the carboxy group of 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid with the amino group of 3,5-dichloropyridin-4-amine. Used for treatment of bronchial asthma and chronic obstructive pulmonary disease. It has a role as an anti-asthmatic drug and a phosphodiesterase IV inhibitor. It is a member of benzamides, an aromatic ether, an organofluorine compound, a chloropyridine and a member of cyclopropanes.

名称と識別子

優先名称
Roflumilast
IUPAC
3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide
現地名
ロフルミラスト
英語名
Roflumilast
分子式
C17H14Cl2F2N2O3
分子量
403.21

名称と別名

Roflumilast162401-32-3DAXAS3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDEDalirespBY217BYK20869ZORYVEBenzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-BY-2170P6C6ZOP5UBYK-20869
名称をさらに表示
ロフルミラスト3-(シクロプロピルメトキシ)-N-(3,5-ジクロロピリジン-4-イル)-4-(ジフルオロメトキシ)ベンズアミドロフルミラスト (JAN)N-(3,5-ジクロロ-4-ピリジル)-3-(シクロプロピルメトキシ)-4-(ジフルオロメトキシ)ベンズアミドBY 217RosterCS-1960RoflostBYK 20869APTA 2217B 9302-107RofluMilas
roflumilastumB9302-107ARQ-154 (Roflumilast foam)DTXSID8044123ARQ-151CHEBI:476573-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide

データベース識別子

CAS
162401-32-3

物性

構造計算による物性補完中

XLogP
4.6
極性表面積
60.5 Ų
水素結合供与体数
1
水素結合受容体数
6
回転可能結合数
7
重原子数
26
形式電荷
0
複雑度
475

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Respiratory system -> Nasal preparations

LogP3.95
SolubilitySparingly soluble
Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Phosphodiesterase 4 Inhibitors

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Dissociation Constants8.74

物理化学的性質

融点
158 °C · 158°C
沸点
430.6 · 430.6±45.0 °C(Predicted)
比重(密度)
1.471 · 1.471±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · -20°C
溶解性
20 mg/mL、透明 · DMSO:可溶20mg/mL、透明
酸解離定数(Pka)
9.89 · 9.89±0.70(Predicted)
外見
粉
色
白からベージュ

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H315 (91.1%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 45 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesSkin Irrit. 2 (91.1%)

毒性情報

Hepatotoxicity · 1 件

In preregistration studies, roflumilast was not associated with serum enzyme elevations or with episodes of clinically apparent liver injury. Since approval of roflumilast, there have been no published reports of hepatotoxicity, and the product label does not mention liver injury as an adverse event.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Roflumilast

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
3
rtecs
CV3325600
hs_code
2933.39.4100
risk_code
36/37/38

化学と産業

薬理情報

ATC Code · 5 件

R03DX07

R - Respiratory system

D - Dermatologicals

QD - Dermatologicals

QR - Respiratory system

Protein BindingPlasma protein binding of roflumilast and its N-oxide metabolite is approximately 99% and 97%, respectively.
Pharmacodynamics · 1 件

Roflumilast and its active metabolite, roflumilast N-oxide, increase cyclic adenosine-3′, 5′-monophosphate (cAMP) in affected cells by inhibiting PDE4. They are highly selective for PDE4 and are effectively inactive against PDEs 1, 2, 3, 5, and 7.

Mechanism of Action · 1 件

Roflumilast and its active metabolite (roflumilast N-oxide) are inhibitors of PDE4. Roflumilast and roflumilast N-oxide inhibition of PDE4 (a major cyclic 3′,5′-adenosine monophosphate (cyclic AMP) metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP. The specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined.

Biological Half-LifeFollowing oral administration, the plasma half-lives of roflumilast and roflumilast N-oxide are 17 hours and 30 hours, respectively.
Metabolism/Metabolites · 1 件

Roflumilast is metabolized to roflumilast N-oxide, the active metabolite of roflumilast in humans, by CYP3A4 and CYP1A2. The N-oxide metabolite is less potent than its parent drug in regards to PDE4 inhibition, but its plasma AUC is approximately 10-fold greater.

FDA Pharmacological Classification · 6 件

0P6C6ZOP5U

ROFLUMILAST

Established Pharmacologic Class [EPC] - Phosphodiesterase 4 Inhibitor

Mechanisms of Action [MoA] - Phosphodiesterase 4 Inhibitors

Roflumilast is a Phosphodiesterase 4 Inhibitor. The mechanism of action of roflumilast is as a Phosphodiesterase 4 Inhibitor.

ROFLUMILAST

関連反応

7 件
反応記録を作成
HRID 42680 の反応式
HRID 42680生成物として
HRID 400326 の反応式
HRID 400326反応物として
HRID 1279392 の反応式
HRID 1279392反応物として
HRID 1911488 の反応式
HRID 1911488生成物として
HRID 1916513 の反応式
HRID 1916513生成物として
HRID 2243787 の反応式
HRID 2243787反応物として
HRID 2378334 の反応式
HRID 2378334生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
PubChem CID
449193
DTXSID
DTXSID8044123
ChEMBL
CHEMBL193240
ChEBI
CHEBI:47657
UNII
0P6C6ZOP5U
EC Number
685-382-2
Nikkaji
J1.365.537E
Merck
14 · 14,8249
安定性
-20 °C · -20°C の DMSO 溶液で最大 3 か月間保存できます。
InChI
InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
InChIKey
MNDBXUUTURYVHR-UHFFFAOYSA-N
SMILES
C(NC1C(Cl)=CN=CC=1Cl)(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1
CAS データベース
162401 · 162401-32-3(CAS DataBase Reference)

化学的性質

化学的特性Crystallin Solid

hazard_code
Xi
safety_code
26
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2STOT SE 3
ストレージクラス
11 - Combustible Solids
Absorption, Distribution and Excretion · 4 件

After a 500mcg dose, the bioavailability of roflumilast is about 80%. In the fasted state, maximum plasma concentrations are reached in 0.5 to 2 hours, while in the fed state, Cmax is reduced by 40%, Tmax is increased by one hour, and total absorption is unchanged. Applied topically, the mean systemic exposure for roflumilast and its N-oxide metabolite in adults was 72.7 ± 53.1 and 628 ± 648 h∙ng/mL, respectively. The mean systemic exposure for roflumilast and its N-oxide metabolite in adolescents was 25.1 ± 24.0 and 140 ± 179 h∙ng/mL, respectively.

Roflumilast is excreted 70% in the urine as roflumilast N-oxide.

Following a single oral dose of 500 mcg, the volume of distribution of roflumilast is approximately 2.9 L/kg.

Plasma clearance of roflumilast following short-term intravenous infusion is approximately 9.6 L/h.

応用分野 · 2 件

説明Roflumilast is a selective, orally active PDE4 inhibitor thatwas approved in Germany in July 2010 as an add-on to bronchodilator treatment for maintenance therapy of severe chronic obstructive pulmonary disorder (COPD) associated with chronic bronchitis in adult patients with a history of frequent exacerbations . Roflumilast and its primary metabolite roflumilast N-oxide are potent and competitive inhibitors of PDE4 and are equipotent against PDE4A, B, andD but inactive against PDE4C and the other ten members of the PDE family (PDEs 1–3, 5–11). Despite its inhibition of PDE4D (IC50=0.80 nM, N-oxide IC50=2.0 nM), roflumilast shows the lowest incidence of nausea (3–5%) among the PDE4 inhibitors investigated in clinical trials.Anti-inflammatory effects of roflumilast have been demonstrated in preclinical cellular and animal models. Roflumilast is synthesized in four steps from 3-(cyclopropylmethoxy)-4-hydroxybenzaldehyde. The difluoromethyl ether is introduced by alkylation of the free phenolic group with chlorodifluoromethane and base. The aldehyde moiety is oxidized to the benzoic acid, which is then converted to an acid chloride and coupled with 3,5-dichloro-4-aminopyridine. Roflumilast is rapidly absorbed and metabolized to its active metabolite, roflumilast N-oxide. Metabolism is mediated by CYP3A4 and CYP1A2.

使用Roflumilast (Daxas) is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM.

補足説明 · 1 件

定義ChEBI: A benzamide obtained by formal condensation of the carboxy group of 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid with the amino group of 3,5-dichloropyridin-4-amine. Used for treatment of bronchial asthma and chronic obstructive pulmonary disease